18F DCFPyL PET Acquisition, Interpretation and Reporting: Suggestions Post Food and Drug Administration Approval.
Hong SongAndrei H IagaruSteven P RowePublished in: Journal of nuclear medicine : official publication, Society of Nuclear Medicine (2021)
18F-DCFPyL was recently approved by the FDA for evaluation prior to definitive therapy and for biochemical recurrence. Here we focus on the key data that justify the clinical use of 18F-DCFPyL, as well as those aspects of protocol implementation and image interpretation that are important to the nuclear medicine physicians and radiologists who will interpret 18F-DCFPyL PET/CT and PET/MR scans.
Keyphrases
- pet ct
- drug administration
- primary care
- positron emission tomography
- randomized controlled trial
- computed tomography
- healthcare
- contrast enhanced
- artificial intelligence
- electronic health record
- magnetic resonance imaging
- big data
- stem cells
- machine learning
- adverse drug
- emergency department
- risk assessment
- quality improvement
- bone marrow
- radiation therapy
- human health